INFECTIOUS DISEASES SOCIETY OF AMERICA for INFECTIOUS DISEASES SOCIETY OF AMERICA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| JONATHAN NURSE | Government Relations Director |
Health Issues HCR
Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
| JONATHAN NURSE | Government Relations Director |
Medicare/Medicaid MMM
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
| JONATHAN NURSE | Government Relations Director |
Budget/Appropriations BUD
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
| JONATHAN NURSE | Government Relations Director |
Medical/Disease Research/Clinical Labs MED
Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA JEZEK | V.P. Public Policy & Government Relations |
| KIMBERLY ANN MILLER | HIV Medicine Association Policy Officer |
| JONATHAN NURSE | Government Relations Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.